We are excited to share that Dr. Karim Tabiti has joined Requalite GmbH team as Chief Strategy Officer effective from 01st March 2023. Dr Tabiti graduated from Technical University of Munich and then Obtained his PhD in molecular biology from the Institute of Molecular Pathology-Vienna University and continued his research career as a Postdoc at Institute of Molecular and Cell Biology (IMCB) in Singapore. Dr Tabiti has then accumulated more than 25 years of experience in Medical device industry companies including Roche, Immune Diagnostic Systems, and in a joint venture of Qiagen. Dr Tabiti then took the responsibility of managing the Biotype Diagnostics GmbH (later Biotype GmbH) as chief executive officer. Dr Tabiti has been acting in the advisory board of several biotech companies since 2013.
Dr Tabiti will be joining Requalite GmbH’s leading team and will resume Business development activities, general Advisory, and Overall Company’s Strategic Planning. We are thrilled to have Dr Karim Tabiti with us and wish him all the success !
Menu
